As of July 8, 2022, the Imaging-Cytometry, Preclinical Evaluation and Technological Development platforms have been officially ISO 9001 certified. An additional guarantee of the quality of the activities of these platforms.
“This certification is part of a continuous improvement quality process in the pursuit of R&D excellence”, commented Frédéric Revah, CEO of Genethon.
ISO 9001 is an international standard that defines the criteria applicable to a quality management system in a company. “The objective is to improve, through audits by a certification body, internal audits or the capture of any anomaly, non-compliance, idea for improvement”, added Vincent Morin, Quality Assurance Manager.
This certification follows an audit carried out in two stages, in May and June 2022, by the AFNOR Certification company. The success of this certification was based on teamwork that mobilized many people internally: R&D platforms, human resources, maintenance, purchasing, quality assurance and general management. The audit did not reveal any non-compliance: the scope audited is therefore certified for three years.